231 related articles for article (PubMed ID: 23320987)
1. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
Stavik B; Tinholt M; Sletten M; Skretting G; Sandset PM; Iversen N
J Hematol Oncol; 2013 Jan; 6():5. PubMed ID: 23320987
[TBL] [Abstract][Full Text] [Related]
2. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor.
Zhang J; Piro O; Lu L; Broze GJ
Circulation; 2003 Aug; 108(5):623-7. PubMed ID: 12835228
[TBL] [Abstract][Full Text] [Related]
3. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.
Tinholt M; Stavik B; Louch W; Carlson CR; Sletten M; Ruf W; Skretting G; Sandset PM; Iversen N
PLoS One; 2015; 10(1):e0117404. PubMed ID: 25617766
[TBL] [Abstract][Full Text] [Related]
4. Caveolae optimize tissue factor-Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor.
Maroney SA; Ellery PE; Wood JP; Ferrel JP; Bonesho CE; Mast AE
Biochem J; 2012 Apr; 443(1):259-66. PubMed ID: 22239091
[TBL] [Abstract][Full Text] [Related]
5. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ.
Maroney SA; Ellery PE; Wood JP; Ferrel JP; Martinez ND; Mast AE
J Thromb Haemost; 2013 May; 11(5):911-8. PubMed ID: 23480518
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells.
Stavik B; Skretting G; Sletten M; Sandset PM; Iversen N
Mol Carcinog; 2010 Nov; 49(11):951-63. PubMed ID: 20886581
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cell-surface TFPIalpha and beta.
Piro O; Broze GJ
J Thromb Haemost; 2005 Dec; 3(12):2677-83. PubMed ID: 16246254
[TBL] [Abstract][Full Text] [Related]
9. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
10. Biology of tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Blood; 2014 May; 123(19):2934-43. PubMed ID: 24620349
[TBL] [Abstract][Full Text] [Related]
11. TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes.
Girard TJ; Tuley E; Broze GJ
Blood; 2012 Feb; 119(5):1256-62. PubMed ID: 22144186
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
Wood JP; Bunce MW; Maroney SA; Tracy PB; Camire RM; Mast AE
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17838-43. PubMed ID: 24127605
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
15. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.
Sevinsky JR; Rao LV; Ruf W
J Cell Biol; 1996 Apr; 133(2):293-304. PubMed ID: 8609163
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.
Girard TJ; Grunz K; Lasky NM; Malone JP; Broze GJ
J Thromb Haemost; 2018 Nov; 16(11):2246-2257. PubMed ID: 30194803
[TBL] [Abstract][Full Text] [Related]
17. Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor.
Maroney SA; Hansen KG; Mast AE
Curr Opin Hematol; 2013 Sep; 20(5):403-9. PubMed ID: 23839295
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.
Salemink I; Franssen J; Willems GM; Hemker HC; Lindhout T
J Biol Chem; 1999 Oct; 274(40):28225-32. PubMed ID: 10497177
[TBL] [Abstract][Full Text] [Related]
19. Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.
Maroney SA; Ferrel JP; Pan S; White TA; Simari RD; McVey JH; Mast AE
J Thromb Haemost; 2009 Jul; 7(7):1106-13. PubMed ID: 19422457
[TBL] [Abstract][Full Text] [Related]
20. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface.
Riesbeck K; Dorling A; Kemball-Cook G; McVey JH; Jones M; Tuddenham EG; Lechler RI
Thromb Haemost; 1997 Dec; 78(6):1488-94. PubMed ID: 9423800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
